Literature DB >> 27546234

Optimal conditions for the performance of a monocyte monolayer assay.

Tik Nga Tong1,2, Emeralda Burke-Murphy2, Darinka Sakac2, Jacob Pendergrast3, Christine Cserti-Gazdewich3, Vincent Laroche4, Donald R Branch1,5,2,3.   

Abstract

BACKGROUND: Various versions of the monocyte monolayer assay (MMA) have been used to assess clinical significance of red blood cell (RBC) alloantibodies in transfusion for more than 35 years. However, the optimal conditions, including anticoagulant used for whole blood samples, temperature and duration of storage, and optimal pH for assessing the response of monocytes to antibody-bound RBCs, have never been clearly delineated. STUDY DESIGN AND METHODS: Whole blood from healthy donors was collected in ACD, EDTA, or heparin and stored at room temperature (RT) versus 4°C for up to 2 days. pH was examined with and without buffers. Phagocytosis of anti-D-opsonized R2 R2 RBCs was used as the positive control for comparison studies. Whole blood was taken into ACD and kept at RT until testing, from patients with or without immune hemolytic anemia.
RESULTS: No significant differences in the phagocytosis of the R2 R2 control RBCs were observed using ACD anticoagulant between freshly drawn or up to 36-hour-stored whole blood kept at RT, regardless of the donor. Physiologic pH during MMA was important for optimal monocyte interactions with antibody-opsonized RBCs. MMA results with patient samples, under optimal conditions, kept up to 30 hours in one instance of long-distance shipment, correlated with clinical hemolysis.
CONCLUSION: MMA can be reliably performed on whole blood samples drawn into ACD and kept at RT for up to 36 hours and when physiologic pH is maintained during the assay. Future studies are required to confirm whether use of these conditions with patient monocytes can provide accurate determination of alloantibody significance in patients requiring blood transfusion.
© 2016 AABB.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27546234     DOI: 10.1111/trf.13766

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  4 in total

1.  Mechanism of increased efficacy of recombinant Fc-μTP-L309C compared to IVIg to ameliorate mouse immune thrombocytopenia.

Authors:  Bonnie J B Lewis; Beth Binnington; Megan Blacquiere; Rolf Spirig; Fabian Käsermann; Donald R Branch
Journal:  EJHaem       Date:  2021-09-29

2.  SCAR: The high-prevalence antigen 013.008 in the Scianna blood group system.

Authors:  Kshitij Srivastava; Jasem Albasri; Omar M Alsuhaibani; Hassan A Aljasem; Marina U Bueno; Tania Antonacci; Donald R Branch; Gregory A Denomme; Willy A Flegel
Journal:  Transfusion       Date:  2020-10-24       Impact factor: 3.337

3.  Use of a Monocyte Monolayer Assay to Evaluate Fcγ Receptor-mediated Phagocytosis.

Authors:  Tik Nga Tong; Donald R Branch
Journal:  J Vis Exp       Date:  2017-01-02       Impact factor: 1.355

4.  Instructions for Flow Cytometric Detection of ASC Specks as a Readout of Inflammasome Activation in Human Blood.

Authors:  Nico Wittmann; Ann-Kathrin Behrendt; Neha Mishra; Lukas Bossaller; Almut Meyer-Bahlburg
Journal:  Cells       Date:  2021-10-26       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.